Investment Thesis
Illumina demonstrates fortress-like financial health with exceptional free cash flow (251M, 23% FCF margin) and conservative leverage (0.25x debt/equity), but faces material operational headwinds with declining revenue (-0.7% YoY) and weak capital returns (ROE 5%, ROA 2%) that are inconsistent with expectations for a life sciences company in a growth industry.
Strengths
- Exceptional free cash flow generation of 251M annually with 23% FCF margin, providing financial flexibility
- Strong gross margins of 66.1% demonstrate pricing power and operational efficiency in core sequencing business
- Fortress balance sheet with conservative leverage (0.25x debt/equity), strong liquidity (1.75x current ratio), 1.1B cash, and 11.6x interest coverage
Risks
- Revenue contraction of -0.7% YoY signals operational challenges in a market segment expected to experience growth
- Extremely weak capital returns (ROE 5%, ROA 2%) indicate poor deployment of 6.6B asset base despite profitable operations
- EPS growth of 170.9% YoY appears driven by financial engineering (likely share buybacks) rather than organic operational improvement given concurrent revenue decline
Key Metrics to Watch
- Revenue growth stabilization and return to positive YoY growth trajectory
- Return on equity and return on invested capital improvement to minimum 10-12% range
- Operating cash flow sustainability and organic earnings contribution excluding one-time items
Financial Metrics
Revenue
1.1B
Net Income
134.0M
EPS (Diluted)
$0.87
Free Cash Flow
251.0M
Total Assets
6.6B
Cash
1.1B
Profitability Ratios
Gross Margin
66.1%
Operating Margin
19.2%
Net Margin
12.3%
ROE
5.0%
ROA
2.0%
FCF Margin
23.0%
Balance Sheet & Liquidity
Current Ratio
1.75x
Quick Ratio
1.36x
Debt/Equity
0.25x
Debt/Assets
0.0%
Interest Coverage
11.61x
Long-term Debt
673.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:55:33.623124 |
Data as of: 2026-03-29 |
Powered by Claude AI